



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 25-11-2009

Mr. Munir Ahmed,  
Director (Admn.),  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE  
WEEKENDING 13-11-2009 TO BE PUBLISHED 26-11-2009 IN THE  
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Mrs. Yasmeen Abbasi)**  
Controller of Patents  
Ph: 99215488

**ENCL:**

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

### 10-11-2009

997/2009	Schering Corporation, USA (Priority 12-11-2008 USA)	“Inhibitors of fatty acid binding protein (fabp)”
998/2009	Schering Corporation USA (Priority 13-11-2008 USA)	“Gamma secretase modulators”
999/2009	Theravance, Inc., USA (Priority 14-11-2008 USA)	“4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds”

### 11-11-2009

1000/2009	Wyeth, USA (Priority 11-11-2008 USA)	“1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands”
1001/2009	Flsmidth A/S, Denmark (Priority 11-12-2008 Denmark)	“Method and plant for heat treatment of raw materials”
1002/2009	Flsmidth A/S, Denmark (Priority 11-11-2008 USA)	“Improved wear-resistant hard surfacing method and article”
1003/2009	Bayer schering Pharma Aktiengesellschaft, Germany (Priority 14-12-2008 Germany)	“Aryl compounds with heterocyclic substituents and their use”
1004/2009	Oerlikon Textile Components GmbH., Germany (Priority 13-11-2008 Germany)	“Top roller for a drafting arrangement”
1005/2009	Sanofi-Aventis, France (Priority 13-11-2008 Europe)	“Method of treating sleep disorders using eplivanserin”
1006/2009	Molycorp Minerals LLC., USA (Priority 11-11-2008 USA)	“Target material removal using rare earth metals”

**12-11-2008**

- 1007/2009 Siemens Vai metals Technologies GmbH. & Co., Austria  
Siemens Aktiengesellschaft,  
Germany  
(Priority 28-11-2008 Austria) “Nozzle for injecting oxygen-containing gas into a pig iron production unit with an injector insert pipe”
- 1008/2009 Astrazeneca AB,  
Sweden.  
(Priority 14-11-2008 USA) “Chemical compounds”
- 1009/2009 Boehringer Ingelheim International GmbH.,  
Germany  
(Priority 14-11-2008 Europe) “New compounds”
- 1010/2009 Sanofi-Aventis,  
France  
(Priority 14-11-2008 France) “Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof”
- 1011/2009 Sanofi-Aventis,  
France.  
(Priority 14-11-2008 France) “Process for the preparation of eplivanserin hemifumarate”

**13-11-2009**

- 1012/2009 Astrazeneca AB,  
Sweden  
(Priority 14-11-2009 USA) “New compounds”
- 1013/2009 Portola Pharmaceuticals, Inc.,  
USA.  
Patheon Inc.,  
Canada  
(Priority 14-11-2008 USA) “Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof”

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

958/1999	SmithKline Beecham p.l.c., United Kingdom SmithKline Beecham Corporation, USA	“A modified release composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione”  A61K 31/433
----------	--	--

**140329**

A pharmaceutical composition which composition comprises an insulin sensitiser and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitiser and the use of such composition in medicine.

277/2004	Euro-Celtique S.A., Luxembourg	“Pharmaceutical composition comprising opioid compound”
----------	-----------------------------------	---

A61K 9/26

**140330**

The present invention relates to a pharmaceutical composition comprising:

- a) an extruded particle comprising an active agent dispersed in a first hydrophobic material; and
- b) a layer comprising a second hydrophobic material disposed about the extruded particle;

wherein the first and second hydrophobic materials sequester the active agent in the pharmaceutical composition.


1054/2004 Akzo Nobel N.V.,  
Netherlands

“Hydroxydimethyl-D-homoestrenones for use in androgenic therapies”

A61K31/56

**140331**

This invention provides 19-nor-D-homosteroids, having a mixed androgenic/progestagenic 5 profile, which are orally active, prevent trabecular bone mineral density (BMD) loss, and which lack liver toxicity, having a structure according to the formula I:



wherein,

R<sup>1</sup> is O, or NOR, with R being hydrogen, C<sub>1-6</sub>) alkyl or C<sub>1-6</sub> acyl, R<sup>2</sup> is methyl or ethyl, and R<sup>3</sup> is hydrogen or C<sub>1-15</sub> acyl.


1055/2004 Basf Aktiengesellschaft,  
Germany

“A 1-(azolin-2-yl)amino-1,2-diphenylethane compound”


CO7D 263/28

**140332**


The present invention relates to 1-(azolin-2-yl)amino-1,2-diphenylethane compound of the general formula I



wherein A is a radical of the formulae A<sup>1</sup> or A<sup>2</sup>:



A<sup>1</sup>



A<sup>2</sup>

and wherein m is 0, 1, 2, 3, 4 or 5, n is 0, 1, 2, 3, 4 or 5, X is sulfur or oxygen, and wherein the variables R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5a</sup>, R<sup>5b</sup>, R<sup>5c</sup>, R<sup>5d</sup> are as defined in the claims.

The invention relates also to a method of combating animal pests, selected from in-sects, arachnids and nematodes and to a method for protecting crops from attack or infestation by insects, arachnids or nematodes, which comprises contacting a crop with a pesticidally effective amount of a 1-(azolin-2-yl)amino-1,2-diphenylethane compounds.


1171/2005 Syngenta Participations  
AG,  
Switzerland

“Process for the production of aniline”


AOIN 43/44

**140333**

The present invention relates to a process for the preparation of compound of formula



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are each independently of the others hydrogen or methyl, by reaction of compound of formula II



wherein R<sub>1</sub> R<sub>2</sub> and R<sub>3</sub> are as defined for formula I and X is bromine or chlorine, with ammonia in the presence of a catalytic amount of at least one copper-containing compound.


901/2007 Eisai R&D Management Co., Ltd., Japan

“Prodrug of cinnamide compound”

CO7D 401/10, A61K 31/454, A61P 25/28, CO7F 9/6558

**140334**

The present invention provides a most suitable prodrug of a cinnamide compound. The prodrug is represented by Formula (I).



wherein R<sub>a</sub> and R<sub>b</sub> each denote a C<sub>1-6</sub> alkyl group or the like; X<sub>a</sub> denotes a methoxy group or a fluorine atom; Y denotes a phosphono group or the like; and A denotes a cyclic lactam derivative.

676/2008 Bayer Schering Pharma Aktiengesellschaft, Germany


“17B-cyano-18a-homo-nor-androst-4-ene compound and the composition comprising the compound”

CO7J 41/00, CO7J 53/00, A61P 5/34, A61K 31/56

**140335**

The 17B-cyano-18a-homo-19-nor-androst-4-ene compound of the present invention possess gestagenic activity. They have the general chemical

formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO<sub>2</sub>R, in which R is hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl, R<sup>4</sup> is hydrogen or halogen, furthermore either: R<sup>6a</sup> R<sup>6b</sup> together from methylene or 1,2-ethanediyl or R<sup>6a</sup> is hydrogen and R<sup>6b</sup> is selected from the group comprising hydrogen, methyl and hydroxymethylene, and R<sup>7</sup> is selected from the group comprising hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>2</sub>-C<sub>3</sub>-alkenyl and cyclopropyl, or: R<sup>6a</sup> is hydrogen and R<sup>6b</sup> and R<sup>7</sup> either together form methylene or are omitted with formation of a double bond between C<sup>6</sup> and C<sup>7</sup>, R<sup>9</sup>, R<sup>10</sup> are hydrogen or are omitted with formation of a double bond between C<sup>9</sup> and C<sup>10</sup>, R<sup>15</sup>, R<sup>16</sup> are hydrogen or together form methylene, R<sup>17</sup> is selected from the group comprising hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl and allyl, at least one of the substituents R<sup>4</sup>, R<sup>6a</sup>, R<sup>6b</sup>, R<sup>7</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> not being hydrogen or R<sup>6b</sup> and R<sup>7</sup> being omitted with formation of a double bond between C<sup>6</sup> and C<sup>7</sup> or being omitted with formation of a double bond between C<sup>1</sup> and C<sup>2</sup>, and moreover comprise its solvate, hydrate, stereoisomer, diastereomer, enantiomer.



762/2008 Musarrat Akhtar,  
Dr. Nighat Sultana,  
PCSIR,  
Karachi,  
Pakistan

“A process for the preparation of herbal based”

A61K 31/00, AO1N 25/32

**140336**

This invention relates to a process for the development of herbal based Nematicide for control of plant parasitic nematodes. This nematicide contains maximum allowable concentration of active ingredient, gallic acid isolated from *Rubus niveus*. This nematicide has been formulated by a

combination of base consisting of garlic extract, micronutrients, macronutrients and humic acid. It is found to be effective on plant parasitic nematodes, enhance the biological activity of soil and also improve the plant growth in comparison of other nematicides. This invention relates to the process for suppression of nematodes containing plant extracts (nematicide) macro nutrients, micro nutrients (Growth promoter), humic acid (Cytokinin/Auxin) and garlic bulbs extract (Fungicide). Synthetic nematicide is costly and hazardous for farmers. It was observed that this economical product is not only effective for suppression of nematodes but also improve the growth of plants. Keeping this fact in view the present invention is carried out to save foreign exchange of our country and would open the door for future exploitation of our natural heritage and its commercialization in modern era.

936/2008 Bayer Schering Pharma  
Aktiengesellschaft,  
Germany

“Device for storage and provision of medicament wafer”

A61J 7/04

**140337**

To monitor the intake of medicament present in wafer form, a device is made available which is suitable for storage and provision of such forms of administration. This device comprises medicament pouches, which are arranged as a stack of pouches and contain medicament wafers, and it has the following features: a) the device has a support 9 which extends parallel to an edge of the medicament pouches 1 and on which, date indicators are arranged, b) a marking 20 is arranged on each of the medicament pouches 1 in such a way that markings 20 arranged on successive medicament pouches 1 in the stack of pouches are each in alignment with successive date indicators. This ensures monitoring of the intake of the wafers.

